Odysseas Manesiotis

Stock Analyst at Exane BNP Paribas

(0.09)
# 4,742
Out of 5,058 analysts
178
Total ratings
29.4%
Success rate
-14.8%
Average return

Stocks Rated by Odysseas Manesiotis

DiaSorin S.p.A.
Jul 7, 2026
Downgraded: Sell
Price Target: €107.00 → €60.00
Current: €77.50
Upside: -22.58%
Lonza Group AG
May 29, 2025
Initiated Coverage: Buy
Price Target: CHF 705.00
Current: CHF 603.80
Upside: n/a
Sartorius Aktiengesellschaft
May 29, 2025
Initiated Coverage: Hold
Price Target: €250.00 → €235.00
Current: €261.80
Upside: n/a
Sartorius Stedim Biotech S.A.
May 29, 2025
Initiated Coverage: Buy
Price Target: €182.00 → €233.00
Current: €219.40
Upside: n/a
CelLBxHealth plc
May 28, 2025
Reiterated: Buy
Price Target: 70p → 30p
Current: 0.80p
Upside: n/a
Qiagen
Feb 24, 2025
Reiterated: Buy
Price Target: $62 → $57
Current: $46.17
Upside: n/a
Oxford Nanopore Technologies plc
Jan 13, 2025
Reiterated: Buy
Price Target: 282p
Current: 210p
Upside: n/a
Tecan Group AG
Nov 15, 2024
Reiterated: Buy
Price Target: CHF 328.00 → CHF 264.00
Current: CHF 247.60
Upside: n/a
Stratec SE
Oct 18, 2024
Reiterated: Buy
Price Target: €50.00
Current: €24.20
Upside: n/a
Siemens Healthineers AG
Sep 25, 2024
Reiterated: Buy
Price Target: €58.20 → €57.80
Current: €40.85
Upside: n/a
Reiterated: Buy
Price Target: €122.20
Current: €87.60
Upside: n/a
Reiterated: Buy
Price Target: 133p → 126p
Current: 71p
Upside: n/a